1Chanan-Khan AA,Giralt S. Importance of a chieving a compiete response in multiple.Myeloma,and the impactofnovel agents[J].{H}Journal of Clinical Oncology,2010,(15):2612-2624.
1Durie BGM, Salmon SE. A clinical staging system for muhiple myeloma. Cancer, 1975,36:842-854.
2Trent L, Miorin M, Facco M, et al. Multiple myeloma plasma cells show different chemokine receptorprofiles at sites of disease activity. Br J Haeinatol, 2007, 138:594-602.
3Aggrawal R, Ghobrial IM, Roodang D, et al. Chemokines in umhiple myeloma. Exp Hemtol, 2006, 34:1289-1295.
4Vande Broek I, Asosingh K, Vanderker ken K, et al. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1,-2 and -3.Br J Cancer, 2003, 88:855- 862.
5Vande Broek I, Leleu X, Schots R, et al. Clinical significance of chemokine receptor (CCR1,CCR2andCXCR4)expression in human myeloma cells: the association with disease aetivity and survival. Haematologica, 2006, 91:200-206.
2Chauhan D, Singh A, Brahmandam M, et al. Combinatitm of proteasome inhibitors bortezomib and NP1-0052 trigger invivo synergistic cytotoxici- ty in multiple myeloma[J].Blood, 2008,111(3) :1654-1664.
3Gerlo S,Haegeman G, Vanden Berghe W. Transcriptional regulation of autocrine IL- 6 expression in multiple myeloma cells[J].Cell Singnal, 2008,20(8): 1489-1496.
4Hoffman R. Hematology-basic principles and practice[M].北京:科学出版社,1998:1403—1410.
6Jagannath S, Barlogie B, Berenson J ,et al.A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma[J]. Br J Haematol, 2004,127 (2) : 165-72.
7Fermand JP, Ravaud P, Chevret S,et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma~ up-front or rescue treatment Results of a multicenter sequential randomized clinical trial[J]. Blood, 1998, 92 (9): 3131-3136.
8Morabito F, Gentile M, Mazzone C, et al. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by borte zomib- thalidomide maintenance (VMPT-VT) versus bortezomib- melphalan-prednisone (VMP) [J]. Blood, 2011,118 (22) : 5759- 5766.
